Whole Genomic Landscape of Advanced EGFR-mutant NSCLC
Status:
Active, not recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a phase 2 single-arm, non-randomized multicentre and tissue acquisition study to
evaluate acquired resistance mechanisms, efficacy, and safety in advanced, EGFR tyrosine
kinase inhibitor-naïve NSCLC patients with EGFR-activating mutations who receive a first-line
osimertinib orally at a dose of 80mg once daily.